Methods, Systems and Devices for Selection and Generation of Genome Edited Clones
Bruker Cellular Analysis, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2017/022518, filed Mar 15, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,239,058 | Methods, Systems and Devices for Selection and Generation of Genome Edited Clones In force · High confidence | Bruker Cellular Analysis, Inc. | In force | High confidence | ||
| US 11,103,870 | Methods, Systems and Devices for Selection and Generation of Genome Edited Clones In force · High confidence | Bruker Cellular Analysis, Inc. | In force | High confidence | ||
| US 11,639,495 | Methods for Selection and Generation of Genome Edited T Cells In force · High confidence | Bruker Cellular Analysis, Inc. | In force | High confidence | ||
| US 11,273,177 | Tumor Infiltrating Cells Engineered to Express a Pro-Inflammatory Polypeptide Lapsed Mar 15, 2026 on the fee record Ended Mar 15, 2026 · High confidence | Bruker Cellular Analysis, Inc. | Lapsed Mar 15, 2026 on the fee record | Ended Mar 15, 2026 | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Bruker Cellular Analysis, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.